Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
8.77
-0.36 (-3.94%)
At close: Mar 24, 2026, 4:00 PM EDT
8.88
+0.11 (1.25%)
Pre-market: Mar 25, 2026, 6:40 AM EDT

Telix Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-5.2737.922.59--
Depreciation & Amortization
21.415.284.16--
Stock-Based Compensation
19.3512.935.85--
Other Adjustments
-7.5714.3826.19--
Change in Receivables
-20.47-37.49-18.62--
Changes in Inventories
-7.64-2.13-6.55--
Changes in Accounts Payable
28.9828.8421.06--
Changes in Accrued Expenses
4.815.214.21--
Changes in Unearned Revenue
-9.13-6.23-3.43--
Changes in Other Operating Activities
-59.07-3.72-6.9-43.53-43.12
Operating Cash Flow
-17.2927.4914.27-43.53-43.12
Operating Cash Flow Growth
-92.60%---
Capital Expenditures
-25.69-9.12-6.31-4.79-0.97
Purchases of Intangible Assets
-18.08-13.07-0.8-4.64-
Purchases of Investments
-0.89-32.91-8.7--
Payments for Business Acquisitions
-221.36-20.66--0.66-
Other Investing Activities
-19.89-10.93-1.03-1.47-1.01
Investing Cash Flow
-285.92-86.69-16.84-11.57-1.98
Long-Term Debt Issued
0.53427.94.192.05-
Long-Term Debt Repaid
0.820.75-0.010.25
Net Long-Term Debt Issued (Repaid)
1.35428.654.192.060.25
Issuance of Common Stock
1.810.664.17123.22.75
Net Common Stock Issued (Repurchased)
1.810.664.17123.22.75
Other Financing Activities
-5.24-11.03-1.27-6.18-0.43
Financing Cash Flow
-3.72416.797.09119.062.07
Effect of Exchange Rate Changes on Cash and Cash Equivalents
8.8-1.890.99--
Net Cash Flow
-298.13355.75.5263.96-43.04
Free Cash Flow
-42.9918.377.97-48.32-44.1
Free Cash Flow Growth
-130.64%---
FCF Margin
-5.35%3.56%2.39%-44.35%-798.67%
Free Cash Flow Per Share
-0.130.050.02-0.16-0.16
Levered Free Cash Flow
-52.1480.4714.62-117.09-102.37
Unlevered Free Cash Flow
-6.0467.1624.09-114.34-98.76
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q